Chidamide

Modify Date: 2024-01-03 18:54:50

Chidamide Structure
Chidamide structure
Common Name Chidamide
CAS Number 743420-02-2 Molecular Weight 390.410
Density 1.3±0.1 g/cm3 Boiling Point 600.2±55.0 °C at 760 mmHg
Molecular Formula C22H19FN4O2 Melting Point N/A
MSDS N/A Flash Point 316.8±31.5 °C

 Use of Chidamide


Chidamide is a synthetic benzamide-type HDAC inhibitor, inhibits HDAC1, HDAC2, HDAC3 and HDAC10 with IC50s of 95, 160, 67 and 78 nM, respectively.

 Names

Name Chidamide
Synonym More Synonyms

 Chidamide Biological Activity

Description Chidamide is a synthetic benzamide-type HDAC inhibitor, inhibits HDAC1, HDAC2, HDAC3 and HDAC10 with IC50s of 95, 160, 67 and 78 nM, respectively.
Related Catalog
Target

HDAC3:67 nM (IC50)

HDAC10:78 nM (IC50)

HDAC1:95 nM (IC50)

HDAC2:160 nM (IC50)

HDAC11:432 nM (IC50)

HDAC8:733 nM (IC50)

In Vitro Chidamide (CS055) at low concentrations dramatically inhibits cell proliferation in each cell line. After Chidamide treatment, cells arrest at the G0/G1 phase in a dose-dependent manner. Western blot analysis indicats that cyclin E1 and E2 protein expression is down-regulated after Chidamide treatment, which is consistent with the cell-cycle analysis. As the changes in cyclin E1 are much more significant than cyclin E2, cyclin E1 is up-regulated in HL60 and K562 cells by lentiviral transduction. The effect on leukaemia proliferation by Chidamide inhibition are largely weakened when cyclin E1 is overexpressed. It is therefore likely that cyclin E1 levels are decreased by Chidamide which induces cell-cycle arrest at the G0/G1 phase[2]. Chidamide causes a significant concentration-dependent inhibitory effect on cell proliferation in comparison to the vehicle-treated cells (P<0.05). The maximal inhibitory effect is reached at 5 μM[3].
In Vivo Inhibition of tumor growth by Chidamide (CS055) treatment is observed in a dose-dependent manner, demonstrating the anti-tumor activity of Chidamide. Control tumors grow to an average volume of 14.51 cm3 after 20 days, and Chidamide-treated tumors grow to 11.68, 11.05 and 8.45 cm3, corresponding to 19.54%, 23.83% and 41.80% growth inhibition respectively. The average tumor mass in animals treated with vehicle is 9.4±2.7 g and is 8.4±2.4 g for animals treated with low-dose Chidamide. In animals treated with a moderate dose of Chidamide, tumor mass is 7.6±1.6 g and those receiving high-dose Chidamide has a tumor mass of 5.4±1.5 g (P<0.01). Additionally, Chidamide treatment prolongs the survival of nude mice bearing HL60 xenografts. Moreover, the level of lipid peroxidation product (MDA), which is a presumptive measure of ROS-mediated injury, is increased in tumor tissue accompanied by treatment of Chidamide, suggesting that Chidamide-induced ROS generation might play a role[2].
Kinase Assay HDAC activity is detected as described in the Colorimetric HDAC Activity Assay kit. Each reaction (100 μL) contains nuclear protein (50 μg) extract from leukaemia cells and HDAC substrate. To test the effect of HDACis, Chidamide (CS055) and MS-275 are added to the mixtures and incubated at 37°C for 1 h. The HDAC activities are measured by a microplate readers at 405 nm. The positive control (only nuclear extract and vehicle) is set as 100% and double-distilled water containing 10 μM Trichostatin A, a known strong HDACi, is used as a negative control and set as 0%[2].
Cell Assay Proliferation of the PaTu8988 cells is evaluated using CCK-8 assay. PaTu8988 cells are randomly into 4 groups and incubated in the absence or presence of concentrations of 0, 1.25, 2.5 and 5 μM) of Chidamide for 48 h. Subsequently, 10 μL CCK-8 is added in each well and incubated for 2 h. The optical density of each well is then measured with a microplate reader at 450 nm. The cell survival rate is calculated using the formula: Cell survival rate (%)=1-(ODctrl-ODsample)/ODctrl×100%[2].
Animal Admin Mice[2] Male BALB/c nude mice (6-week-old) are used. Each mouse is inoculated in the right axilla with 2×107 HL60 cells suspended in 0.2 mL of PBS. At 0.5 week later, mice bearing tumours reaching 200±100 mm3 are randomized into four groups (n=8) and received 0.1% sodium carboxyl methylcellulose as a vehicle and 12.5, 25 or 50 mg/kg of body mass Chidamide daily by gavage for 20 days. Tumour volume and body mass are measured every day.
References

[1]. Ning ZQ, et al. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. Cancer Chemother Pharmacol. 2012 Apr;69(4):901-9.

[2]. Gong K, et al. CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells. Biochem J. 2012 May 1;443(3):735-46.

[3]. Zhao B, et al. Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor by modulating the ratio of Bax/Bcl-2 and P21 in pancreatic cancer. Oncol Rep. 2015 Jan;33(1):304-10.

 Chemical & Physical Properties

Density 1.3±0.1 g/cm3
Boiling Point 600.2±55.0 °C at 760 mmHg
Molecular Formula C22H19FN4O2
Molecular Weight 390.410
Flash Point 316.8±31.5 °C
Exact Mass 390.149200
PSA 97.11000
LogP 2.20
Appearance of Characters white solid
Vapour Pressure 0.0±1.7 mmHg at 25°C
Index of Refraction 1.691
Storage condition -20℃

 Synonyms

N-(2-Amino-5-fluorophenyl)-4-({[(2E)-3-(3-pyridinyl)-2-propenoyl]amino}methyl)benzamide
Benzamide, N-(2-amino-5-fluorophenyl)-4-[[[(2E)-1-oxo-3-(3-pyridinyl)-2-propen-1-yl]amino]methyl]-
Chidamide
Top Suppliers:I want be here




Get all suppliers and price by the below link:

Chidamide suppliers


Price: $144/10mM*1mLinDMSO

Reference only. check more Chidamide price